https://scholars.lib.ntu.edu.tw/handle/123456789/113990
標題: | Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials | 作者: | Dong, Yaa-Hui HSIEN-HO LIN Shau, Wen-Yi Wu, Yun-Chun CHIA-HSUIN CHANG Lai, Mei-Shu |
公開日期: | 2013 | 卷: | 68 | 期: | 1 | 起(迄)頁: | 48-56 | 來源出版物: | Thorax | 摘要: | Background The active-treatment comparative safety information for all inhaled medications in patients with chronic obstructive pulmonary disease (COPD) is limited. We aimed to compare the risk of overall and cardiovascular death for inhaled medications in patients with COPD. Methods Through systematic database searching, we identified randomised controlled trials of tiotropium Soft Mist Inhaler, tiotropium HandiHaler, long-acting beta 2 agonists (LABAs), inhaled corticosteroids (ICS), and LABA-ICS combination with at least a 6-month treatment duration. Direct comparison and mixed treatment comparison (MTC) meta-analyses were conducted to estimate the pooled ORs of death for each comparison. Results 42 trials with 52 516 subjects were included. The MTC meta-analysis with the fixed effect model indicated tiotropium Soft Mist Inhaler was associated with an universally increased risk of overall death compared with placebo (OR 1.51; 95% CI 1.06 to 2.19), tiotropium HandiHaler (OR 1.65; 95% CI 1.13 to 2.43), LABA (OR 1.63; 95% CI 1.10 to 2.44) and LABA-ICS (OR 1.90; 95% CI 1.28 to 2.86). The risk was more evident for cardiovascular death, in patients with severe COPD, and at a higher daily dose. LABA-ICS was associated with the lowest risk of death among all treatments. No excess risk was noted for tiotropium HandiHaler or LABA. The results were similar for MTC and direct comparison meta-analyses, with less precision in the random effects model. Conclusion Our study provided a comparative safety spectrum for each category of inhaled medications. Tiotropium Soft Mist Inhaler had a higher risk of mortality and should be used with caution. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/259358 http://ntur.lib.ntu.edu.tw/bitstream/246246/259358/1/index.html |
DOI: | 10.1136/thoraxjnl-2012-201926 | SDG/關鍵字: | beta 2 adrenergic receptor stimulating agent; corticosteroid; long acting drug; placebo; tiotropium bromide; adult; aged; article; cause of death; chronic obstructive lung disease; clinical effectiveness; controlled study; disease association; disease severity; drug effect; drug efficacy; drug fatality; drug safety; female; heart death; human; major clinical study; male; meta analysis; priority journal; randomized controlled trial (topic); risk assessment; survival rate; systematic review; treatment duration |
顯示於: | 流行病學與預防醫學研究所 |
檔案 | 描述 | 大小 | 格式 | |
---|---|---|---|---|
index.html | 23.18 kB | HTML | 檢視/開啟 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。